On Thursday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $169.63 which represents a decrease of $-0.72 or -0.42% from the prior close of $170.35. The stock opened at $170 and touched a ...
Asking dollar volume for luxury houses totals $124 million, with most properties selling “at a pretty robust pace.” ...
On Friday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $199.5 which represents a decrease of $-1.01 or -0.50% from the prior close of $200.51. The stock opened at $201.16 and touched a ...
If it does prove to be the end of emraclidine for schizophrenia, that looks set to benefit Bristol-Myers Squibb, which ended ...
In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The ...
AbbVie Inc. (NYSE:ABBV – Get Free Report)’s stock price shot up 0.1% during trading on Friday after Citigroup raised their price target on the stock from $215.00 to $226.00. Citigroup currently has a ...
Pharmaceutical company AbbVie (ABBV) is the latest stock in my portfolio to announce a higher dividend. Accompanying its third-quarter earnings report, AbbVie declared a 5.8% increase in its ...
In a report released yesterday, Louise Chen from Cantor Fitzgerald maintained a Buy rating on AbbVie (ABBV – Research Report), with a ...
AbbVie’s deal team is having a busy week. Days after inking a $1.4 billion buyout, the drugmaker has put up the same again in biobucks to secure options on multispecific T-cell engagers from ...
NORTH CHICAGO, Ill. and BRANFORD, Conn., Oct. 31, 2024 (GLOBE NEWSWIRE) -- AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback